



## The Schistosomiasis Action Plan: next generation research on the road towards elimination

**8.30am – 3pm, 28<sup>th</sup> of October 2018**  
**Ile De France I, Marriott Hotel, New Orleans**

Welcome	Organisers and co-chairs of GSA Research Working group	Poppy Lamberton & Jutta Reinhard-Rupp
8:30-9:00	Coffee and registration	
9:00-9:15	Welcome, GSA update & Schistosomiasis Action Plan	David Rollinson (Director GSA)
Group 1:	COR-NTD updates from schistosomiasis sessions	Chair: Alan Fenwick
9:15 – 9:35	<p>Outcomes of COR NTD schistosomiasis sessions:</p> <ol style="list-style-type: none"> <li>1. Identifying and responding to non-responsive schistosomiasis and STH areas following treatment.</li> <li>2. Identify the operational research needs for Precision Mapping.</li> <li>3. Large-scale evidence of success: implementing and evaluating national mass drug administration programmes for soil-transmitted helminths and schistosomiasis.</li> <li>4. A behavioural change toolkit for creative problem solving during routine MDA and endgame interventions.</li> </ol>	<p>Lead 1: <b>Michael French</b> (RTI)</p> <p>Lead 2: <b>Fiona Fleming</b> (SCI) &amp; <b>Louis-Albert Tchuem Tchuente</b> (Cameroon)</p> <p>Lead 3: <b>Suzy Campbell</b> (Evidence Action) &amp; <b>Lynsey Blair</b> (SCI)</p> <p>Lead 4: <b>Goyette Chami</b> (Uni of Cambridge)</p>
9:35-10:00	Discussion	
Group 2	FGS and morbidity	Chair: Jutta Reinhard-Rupp
10:00-10:10	FGS, HIV and the launch of the UNAIDS-WHO report	Pamela Mbabazi
10:10-10:20	FGS and early detection morbidity markers	Amaya Bustinduy
10.20-10.30	MORBID	Evan Secor
10:30-11:00	Discussion	
11.00-11.30	Coffee	

<b>Group 3</b>	<b>Advances in vaccines, diagnostics and snail control</b>	<b>Chair: Poppy Lamberton</b>
11:30 -11:40	Vector control using new molecular technologies	Nic Wheeler
11.40-11.50	Dissecting immune responses following controlled human schistosomiasis infections to guide vaccine design	Meta Roestenberg
11:50-12:00	Discovery of <i>S. haematobium</i> diagnostic antigens using an 'immunomics' approach	Alex Loukas
12:00 –12:10	Sm-p80-based schistosomiasis vaccine: Preparation for human clinical trials	Afzal Siddiqui
12.10-12.20	Phase 1 trials of the Sm-TSP-2 schistosomiasis vaccine	Maria-Elena Bottazzi
12.20-12:50	Discussion	
12.50-14.00	Networking & Lunch courtesy of the GSA	
<b>Group 4</b>	<b>Progress towards schistosomiasis elimination</b>	<b>Chair: David Rollinson</b>
14.00-14.10	Modelling insights into schistosomiasis elimination	Jaspreet Toor
14:10-14:20	Programme managers view on elimination in Zanzibar	Fatma Kabole
14:20-14:30	Programmatic challenges for elimination – ESPEN	Pauline Mwinzi
14:30-15:00	Discussion	
<b>15.00</b>	<b>Meeting closes – feedback welcome</b>	